Loading
A phase 1/2 trial of Pucotenlimab, Bevacizumab in hepatocellular carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) is a phase 1/2 interventional study registered as NCT07479485 by Lepu Biopharma Co., Ltd., with 160 participants planned, started 2026-04-08 and due to reach its primary completion in 2028-04. Interventions recorded: MRG006A, Pucotenlimab, Bevacizumab, PD1/VEGF antibody, TKI. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lepu Biopharma, Pucotenlimab.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Hepatocellular carcinoma.
Shares Lepu Biopharma, Pucotenlimab.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/